Walther-Straub-Institute of Pharmacology and Toxicology, Ludwig-Maximilians-University, Munich, Germany.
Oncogene. 2012 Aug 30;31(35):3913-23. doi: 10.1038/onc.2011.560. Epub 2011 Dec 5.
Deleted in Liver Cancer 1 (DLC1) is a tumor suppressor whose allele is lost in 50% of liver, breast, lung and 70% of colon cancers. Here, we show that the transcriptional coactivators Megakaryoblastic Leukemia 1 and 2 (MKL1/2) are constitutively localized to the nucleus in hepatocellular and mammary carcinoma cells that lack DLC1. Moreover, DLC1 loss and MKL1 nuclear localization correlate in primary human hepatocellular carcinoma. Nuclear accumulation of MKL1 in DLC1-deficient cancer cells is accomplished by activation of the RhoA/actin signaling pathway and concomitant impairment of MKL1 phosphorylation, which results in constitutive activation of MKL1/2 target genes. We provide evidence that MKL1/2 mediates cancerous transformation in DLC1-deficient hepatocellular and mammary carcinoma cells. Depletion of MKL1/2 suppresses cell migration, cell proliferation and anchorage-independent cell growth induced by DLC1 loss.
肝癌缺失基因 1(DLC1)是一种肿瘤抑制因子,其等位基因在 50%的肝癌、乳腺癌、肺癌和 70%的结肠癌中丢失。在这里,我们发现转录共激活因子巨核细胞白血病 1 和 2(MKL1/2)在缺乏 DLC1 的肝癌和乳腺癌细胞中持续定位于细胞核。此外,DLC1 缺失和 MKL1 核定位在原发性人肝癌中相关。DLC1 缺陷型癌细胞中 MKL1 的核积累是通过 RhoA/肌动蛋白信号通路的激活和 MKL1 磷酸化的同时损伤来实现的,导致 MKL1/2 靶基因的持续激活。我们提供的证据表明,MKL1/2 在 DLC1 缺陷型肝癌和乳腺癌细胞中介导癌变。MKL1/2 的耗竭抑制了由 DLC1 缺失诱导的细胞迁移、细胞增殖和非锚定依赖性细胞生长。